Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CAMKK1 | Q8N5S9 | 2/20 | 0.31 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | SGK1 | O00141 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 0.30 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26312977 | 0.80 | FEN1 (0.38) | ALOX5APFEN1ADORA2AADORA1KDM4E | |
| SCHEMBL21821168 | 0.78 | NPC1 (0.36) | ALOX5APFEN1 | |
| SCHEMBL20515187 | 0.75 | ALOX5 (0.36) | — | |
| SCHEMBL19434145 | 0.74 | LDHA (0.36) | ADORA2AADORA1SMN1; SMN2DHODH | |
| SCHEMBL21821186 | 0.71 | CHRNB2 (0.35) | — | |
| SCHEMBL17516214 | 0.71 | — | — | |
| SCHEMBL26312971 | 0.70 | NPC1 (0.42) | ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL29444276 | 0.66 | NPC1 (0.40) | LMNASMN1; SMN2 | |
| SCHEMBL21244195 | 0.66 | NPC1 (0.40) | LMNASMN1; SMN2 | |
| SCHEMBL22134625 | 0.66 | ALOX5AP (0.39) | ALOX5APFEN1CAMKK1CAMKK2SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125406-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522625-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230322829-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-12 | — | — | US | disclosed |
| US-11718634-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20200087334-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087334-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | ALOX5AP 1952/4885FEN1 1075/4885ADORA2A 3073/4885 |
| US-20260125406-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | EED, CTNND1, EEF1D | ALOX5AP 3897/4885FEN1 3933/4885ADORA2A 2942/4885 |
| US-20230322829-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | ALOX5AP 1906/4885FEN1 988/4885ADORA2A 2916/4885 |
| US-11718634-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, ICOSLG | ALOX5AP 1952/4885FEN1 1075/4885ADORA2A 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.